消化道肿瘤患者化疗前后血浆胃动素和降钙素基因相关肽的变化

The compare changes of motilin and calcinin gene related-peptide in chemotherapy for digestive tumor

目的检测消化道肿瘤患者化疗前后和胃良性疾病者的血浆胃动素（MTL）、降钙素基因相关肽（CGRP）含量，了解化疗前后MTL、CGRP含量变化及其临床意义。方法采用放射免疫分析法测定消化道肿瘤40例（其中胃癌16例，原发性肝癌8例，结、直肠癌8例，其他癌肿8例）及胃良性疾病患者20例的MTL、CGRP含量，并进行比较。结果胃癌和结直肠癌化疗后血浆MTL均显著低于治疗前（P〈0．05），原发性肝癌和其他癌症患者血浆MTL含量化疗前后比较差异无统计学意义（P〉0．05）；原发性肝癌化疗后CGRP含量比化疗前显著降低（P〈0．01），结直肠癌患者血浆CGRP化疗后比化疗前明显降低（P〈0．05），原发性肝癌、结直肠癌患者血浆CGRP化疗前后比较差异有统计学意义，胃癌及其他癌症化疗前后比较差异无统计学意义（P〉0．05）。结论化学治疗前后血浆MTL和CGRP含量检测对判断消化道肿瘤的治疗效果可能有所帮助。

Objective To study clinical significances of motilin （MTL） and calcinin gene related-peptide （CGRP） in gastrointestinal cancer. It was investigated whether there were any changes of them before and after the chemotherapy of gastrointestinal cancer and clinical value. Methods MTL and CGRP levels in the plasma of 40 cases were investigated before and after the chemotherapy of gastrointestinal cancer patients（16 cases with gastric cancer,8 cases with hepatic cancer,8 cases with colorectal cancer,8 cases was with other malignant tumor）,20 cases were non-gastric malignant diseases as controls. They were measured by RIA（radioimmunoassay）. Results （1）The plasma-MTL levels in the patients with gastric, hepatic, colorectal and other malignant cancer after they got chemotherapy were lower than those before（ P 〈 0.05 ）. Gastric cancer patients had the highest plasma MTL level in all of those digestive tumor cases. There was no significant difference of plasma MTL levels between the patients with pancreatic cancer, hepatic cancer, benign gastric diseases and the controls （P 〉 0.05 ）. （2）The plasma CGRP levels of hepatic cancer, coloreetal cancer and benign gastric diseases after they gotchemotherapy were lower than those before（P 〈 0.05）. Hepatic cancer patients had the highest plasma CGRP level in all of those digestive tumor cases（P 〈 0.01 ）. There was no significant found in other patients. （3）No differences were seen in MTL and CGRP levels between other malignant ones（P 〉0.05）. Conclusion The results suggest that the plasma levels of MTL in the chemotherapy of digestive cancer may monitor the recurrence of upper digestive tract tumor have high specificity,and the plasma level of CGRP may evaluate the treatment to the primary hepatocarcinoma cancer.